Black Diamond Therapeutics Inc
(NAS:BDTX)
$
3.31
0.09 (2.8%)
Market Cap: 187.03 Mil
Enterprise Value: 82.76 Mil
PE Ratio: 0
PB Ratio: 1.68
GF Score: 41/100 Black Diamond Therapeutics Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Apr 14, 2022 / 02:00PM GMT
Release Date Price:
$3.41
(-6.06%)
Arlinda Lee
Canaccord Genuity LLC - Analyst
Good morning. My name is Arlinda Lee, and I'm a senior biotech analyst at Canaccord. I am pleased Black Diamond's Founder, President, and Chief Executive Officer, David Epstein, is joining us for a fireside chat to discuss their proprietary MAP platform and clinical candidate pipeline.
David, welcome.
David Epstein
Black Diamond Therapeutics, Inc. - Co-Founder, President, & CEO
Thank you, Arlinda, and good morning, everyone.
Questions & Answers
Arlinda Lee
Canaccord Genuity LLC - Analyst
Can we maybe kick off our discussion by talking about your platform? Can you please describe the MAP platform? How does the platform work to identify and validate novel mutations? What differentiates MAP platform from what other companies are doing in targeted oncology?
David Epstein
Black Diamond Therapeutics, Inc. - Co-Founder, President, & CEO
Sure, happy to do that. I'm going to use some slides, but feel free
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot